Author:
Perez Edith A.,Roche Patrick C.,Jenkins Robert B.,Reynolds Carol A.,Halling Kevin C.,Ingle James N.,Wold Lester E.
Reference27 articles.
1. HER-2 as a prognostic, predictive, and therapeutic target in breast cancer;Perez;Cancer Control,1999
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 987;235:177-182.
3. Relevance of p185 HER-2/neu oncoprotein quantification in human primary breast carcinoma;Bermont;Breast Cancer Res Treat,2000
4. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease;Cobleigh;J Clin Oncol,1999
5. Final report: weekly (W) Herceptin (H) and Taxol (T) for metastatic breast cancer (MBC): analysis of efficacy by HER2 immunophenotype [immunohistochemistry (IHC)] and gene amplification [fluorescent in-situ hybridization (FISH)] [abstract];Seidman;Proc Am Soc Clin Oncol,2000
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献